Breaking News

Bayer, Regeneron, Santen in EYLEA Promotion Pact

Will co-promote wet AMD drug in Japan

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bayer HealthCare’s Japanese subsidiary, Bayer Yakuhin and Regeneron Pharmaceuticals have entered into a co-promotion agreement with Santen Pharmaceutical Co. for EYLEA (aflibercept) Injection in Japan. Bayer Yakuhin has submitted an application for marketing authorization to the Ministry of Health, Labor and Welfare (MHLW) for EYLEA for the treatment of neovascular age-related macular degeneration (wet AMD). “With this agreement and upon marketing authorization, a newly formed Bayer Yakuh...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters